Angiogenic Biomarkers and Neonatal Outcomes in Suspected Preeclampsia: Retrospective Cohort Study
Open Access
- 8 December 2025
- journal article
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 133 (4) , 779-787
Abstract
Placental growth factor (PlGF) and soluble fms‐like tyrosine kinase 1 (sFlt1) are two biomarkers associated with placental function and the sFlt‐1/PlGF ratio is frequently used for risk assessment and prediction of preeclampsia in pregnancy. Objective: To assess the association between elevated sFlt‐1/PlGF ratio and adverse neonatal outcomes in pregnancies with suspected preeclampsia. Design: Retrospective cohort study. Setting: A tertiary centre in Hong Kong. Population: 162 singleton neonates delivered between January 2020 and May 2023 from pregnancies complicated by suspected preeclampsia and sFlt‐1/PlGF taken within 4 weeks before delivery. Methods: Pregnant women with suspected preeclampsia were recruited with analysis of serum Flt‐1 and PlGF. Neonatal outcomes were compared between neonates from pregnancies with sFlt‐1/PlGF ratio ≥ 85 (high‐risk group) and < 85 (low‐risk group). Main Outcome Measures: Neonatal outcomes including growth, respiratory, gastrointestinal, and metabolic complications. Results: Logistic regression analysis showed that after adjustment for gestational age, preeclampsia and newborn sex, sFlt‐1/PlGF ratio ≥ 85 was significantly associated with small‐for‐gestation (SGA; aOR = 2.52, 95% C.I. = 1.12–5.60), feeding intolerance (aOR = 3.03, 95% C.I. = 1.01–9.09), need for parenteral nutrition (PN; aOR = 11.19, 95% C.I. = 2.23–56.29), prolonged PN (aOR = 6.92, 95% C.I. = 1.43–33.39), hospitalisation over 7 and 30 days (aOR = 3.62, 95% C.I. = 1.20–10.87 and aOR = 7.04, 95% C.I. = 1.08–45.80 respectively). Linear regression showed a significant association between sFlt‐1/PlGF ratio and duration of respiratory support, PN and duration of hospital stay. Conclusions: An elevated maternal sFlt‐1/PlGF ratio within 4 weeks of delivery is significantly associated with adverse neonatal outcomes including SGA, gastrointestinal complications, prolonged parenteral nutrition and prolonged hospitalisation.Keywords
Funding Information
- Health and Medical Research Fund (08191526)
- Ministry of Science and Technology (2021YFC2701600)
This publication has 51 references indexed in Scilit:
- Prevention of preeclampsia with aspirinAmerican Journal of Obstetrics and Gynecology, 2022
- Clinical tools and biomarkers to predict preeclampsiaEBioMedicine, 2021
- Aspirin Use to Prevent Preeclampsia and Related Morbidity and MortalityJAMA, 2021
- Biomarkers for the Diagnosis of Neonatal SepsisClinics in Perinatology, 2021
- Preeclampsia—Pathophysiology and Clinical PresentationsJACC, 2020
- Association of Use of the Neonatal Early-Onset Sepsis Calculator With Reduction in Antibiotic Therapy and SafetyJAMA Pediatrics, 2019
- Preeclampsia; short and long-term consequences for mother and neonateEarly Human Development, 2016
- Angiogenic balance (sFlt-1/PlGF) and preeclampsiaAnnales d'Endocrinologie, 2016
- Implementation of the sFlt‐1/PlGF ratio for prediction and diagnosis of pre‐eclampsia in singleton pregnancy: implications for clinical practiceUltrasound in Obstetrics & Gynecology, 2015
- Neonatal Apnea: What's New?Pediatric Pulmonology, 2008